Concerns have arisen surrounding plasma donation practices in Canada after Health Canada identified multiple operational deficiencies at a Grifols collection centre in Winnipeg. These findings followed the tragic death of a donor, Rodiyat Alabede, in October 2025, and a subsequent fatality in January 2026. Despite the gravity of the situation, Health Canada faced criticism for its delayed response to publicize these issues, raising questions about the safety protocols in place at the only major commercial plasma collector in the country.
A Closer Look at Health Canada’s Findings
The report, dated December 22, 2025, emerged from a federal inspection prompted by Alabede’s death, which occurred shortly after her plasma donation at Grifols’ Taylor Avenue facility. Health Canada initiated a compliance verification process nearly a month later, involving site visits and staff interviews. The findings were alarming. The report highlighted five major areas of concern, including inadequate analysis of the incidents, insufficient staff training, and failures in adhering to standard operating procedures.
Health Canada explicitly noted that staff often did not follow protocols when donation machines emitted alarms, indicating high pressure in a donor’s vein. In one instance, an alarm sounded during a collection, yet staff continued with the process. Such lapses in protocol raise significant safety alarms for donors, potentially compromising their health.
Operational Practices Under Scrutiny
The deficiencies identified by Health Canada paint a troubling picture of Grifols’ operational practices. According to the December report, 14 of the 20 staff members in the donation hall had been hired since February 2025, suggesting a lack of experienced personnel. Staff training procedures were also found lacking; employees could repeatedly fail a training quiz four times before any follow-up was conducted, with no variation in the quiz content.
Moreover, the report indicated that proper protocols for monitoring and responding to alerts were not consistently enacted. This included improper setup of equipment and lack of documentation. Alarmingly, during Health Canada’s visit, there were no supervisors present in the donation hall, raising further concerns about oversight and management at the facility.
Grifols Responds to Regulatory Pressure
In response to these serious findings, Grifols has stated that it is committed to addressing the concerns raised by Health Canada. The company acknowledged that all its centres are under federal oversight and that it has submitted detailed action plans aimed at enhancing compliance and preventing future occurrences.
Mark Johnson, a spokesperson for Health Canada, confirmed that the department is currently evaluating the corrective actions proposed by Grifols and will take further measures if necessary. However, the timeline for these actions remains unclear, leading to ongoing worries about donor safety.
Systemic Issues in Plasma Collection Practices
The situation at Grifols is emblematic of broader systemic issues within Canada’s plasma collection framework. The recent incidents have highlighted a troubling gap between operational safety and regulatory oversight. Jason MacLean, chair of the Canadian Health Coalition, emphasized the need for accountability, suggesting that both Grifols and Health Canada must respond more effectively to ensure donor safety.
The implications of these findings extend beyond the immediate concerns of Grifols’ operations; they touch upon the broader conversation surrounding the ethics of paid plasma donation and the urgent need for stringent oversight of health practices.
Why it Matters
The revelations surrounding Grifols’ plasma collection practices serve as a stark reminder of the vulnerabilities present in the healthcare system, particularly in the realm of donor safety. With Canada relying heavily on plasma-derived medicines—spending approximately $1 billion annually on such products—ensuring robust safety protocols is paramount. The tragedies of Rodiyat Alabede and others must not be in vain. They highlight an urgent need not only for immediate regulatory reform but also for a comprehensive reassessment of how plasma donation practices are managed across the nation. The health and well-being of countless donors depend on it.
